A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Saved in:
| Title: | A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. |
|---|---|
| Authors: | Gan HK; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. hui.gan@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia. hui.gan@onjcri.org.au.; Department of Medical Oncology, Austin Health, Melbourne, Australia. hui.gan@onjcri.org.au., Parakh S; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Melbourne, Australia., Lee FT; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Tebbutt NC; Department of Medical Oncology, Austin Health, Melbourne, Australia., Ameratunga M; Department of Medical Oncology, Austin Health, Melbourne, Australia., Lee ST; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia., O'Keefe GJ; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Gong SJ; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Vanrenen C; Department of Medical Oncology, Austin Health, Melbourne, Australia., Caine J; Department of Medical Oncology, Austin Health, Melbourne, Australia., Giovannetti M; Ludwig Cancer Research, New York, NY, USA., Murone C; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Paine C; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Macri MJ; Ludwig Cancer Research, New York, NY, USA., Kotsuma M; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Senaldi G; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Venhaus R; Ludwig Cancer Research, New York, NY, USA., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia. |
| Source: | Investigational new drugs [Invest New Drugs] 2022 Aug; Vol. 40 (4), pp. 747-755. Date of Electronic Publication: 2022 Apr 11. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
